Aura Biosciences Statistics
Total Valuation
AURA has a market cap or net worth of $375.14 million. The enterprise value is $219.84 million.
Important Dates
The next estimated earnings date is Wednesday, March 26, 2025, before market open.
| Earnings Date | Mar 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AURA has 49.95 million shares outstanding. The number of shares has increased by 32.55% in one year.
| Current Share Class | 49.95M |
| Shares Outstanding | 49.95M |
| Shares Change (YoY) | +32.55% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 1.66% |
| Owned by Institutions (%) | 47.71% |
| Float | 31.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.14 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.47, with a Debt / Equity ratio of 0.11.
| Current Ratio | 12.47 |
| Quick Ratio | 11.85 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.99% and return on invested capital (ROIC) is -31.82%.
| Return on Equity (ROE) | -50.99% |
| Return on Assets (ROA) | -30.22% |
| Return on Invested Capital (ROIC) | -31.82% |
| Return on Capital Employed (ROCE) | -48.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$935,011 |
| Employee Count | 89 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AURA has paid $225,000 in taxes.
| Income Tax | 225,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.18% in the last 52 weeks. The beta is 0.29, so AURA's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -13.18% |
| 50-Day Moving Average | 8.05 |
| 200-Day Moving Average | 8.48 |
| Relative Strength Index (RSI) | 38.25 |
| Average Volume (20 Days) | 143,929 |
Short Selling Information
The latest short interest is 1.21 million, so 2.43% of the outstanding shares have been sold short.
| Short Interest | 1.21M |
| Short Previous Month | 1.41M |
| Short % of Shares Out | 2.43% |
| Short % of Float | 3.83% |
| Short Ratio (days to cover) | 9.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -93.09M |
| Pretax Income | -80.50M |
| Net Income | -83.22M |
| EBITDA | -91.84M |
| EBIT | -93.09M |
| Earnings Per Share (EPS) | -$1.72 |
Full Income StatementBalance Sheet
The company has $174.38 million in cash and $19.08 million in debt, giving a net cash position of $155.29 million or $3.11 per share.
| Cash & Cash Equivalents | 174.38M |
| Total Debt | 19.08M |
| Net Cash | 155.29M |
| Net Cash Per Share | $3.11 |
| Equity (Book Value) | 174.67M |
| Book Value Per Share | 3.51 |
| Working Capital | 168.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$73.24 million and capital expenditures -$1.27 million, giving a free cash flow of -$74.51 million.
| Operating Cash Flow | -73.24M |
| Capital Expenditures | -1.27M |
| Free Cash Flow | -74.51M |
| FCF Per Share | -$1.49 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |